NVS vs Peers Stock Comparison

Novartis Ag Prices as of Oct 26, 2026 Peers: Industry group
NVS Novartis Ag
$153.75 +5.7% 1M +17.9% 1Y
Market cap
$293.38B
P/E
18.9x
Revenue (TTM)
$54.77B
Div. yield
3.08%
Pharmaceuticals Healthcare

Percentile Scorecard

NVS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNVS
Valuation 87 #37 of 275
Growth 53 #120 of 253
Profitability 96 #9 of 224
Financial Health 43 #170 of 296
Shareholder Returns 78 #28 of 126
Overall 71
  • NVS ranked among 305 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNVSSPY
1 month +5.7% -0.8%
3 months -1.5% +3.5%
6 months +6.6% +7.0%
Year to date +11.5% +12.2%
1 year +17.9% +13.0%
3 years +66.6% +86.3%
3 years, per year +18.6% +23.1%
5 years +85.8% +68.6%
5 years, per year +13.2% +11.0%
10 years +116.2% +258.0%
10 years, per year +8.0% +13.6%

Risk

MeasureNVSSPY
Volatility, 1Y 27.8% 12.7%
Downside volatility, 1Y 30.7% 12.7%
Beta vs S&P 500, 1Y 0.33 1.00
Return / volatility, 1Y 0.64 1.02
Max drawdown, 5Y -20.4% -25.4%
From 52-week high -8.8% -1.8%
52-week high $168.62 $779.14
52-week low $121.80 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNVS
P/E now vs peer median 18.9xmedian 10.4x
P/S now vs peer median 5.4xmedian 6.4x
EV/EBITDA now vs peer median —median 10.7x
P/FCF now vs peer median 15.1xmedian 12.5x
P/B now vs peer median 7.0xmedian 1.6x
PEG now vs peer median 0.58median 0.29

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNVS
Revenue $54.77B
Gross profit $42.37B
Operating income $17.10B
Net income $12.75B
Free cash flow $19.38B
R&D $11.69B
EPS (diluted) $8.07
Cash & equivalents $7.62B
Total debt $31.01B
Shares (diluted) 1.96B
Enterprise value $257.77B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNVS
P/E 18.9x
P/FCF 15.1x
P/Operating cash flow 16.0x
P/S 5.4x
P/B 7.0x
P/Tangible book -2,292x
EV/EBITDA –
EV/EBIT 17.3x
EV/Revenue 5.4x
EV/FCF 15.2x
EV/Operating cash flow 16.1x
PEG (3Y EPS CAGR) 0.58

Growth

14 metrics
MetricNVS
Revenue growth (1Y) 2.8%
Revenue CAGR (3Y) 8.1%
Gross profit growth (1Y) 0.7%
Gross profit CAGR (3Y) 9.5%
Operating income growth (1Y) 2.5%
Operating income CAGR (3Y) 23.8%
Net income growth (1Y) -6.5%
Net income CAGR (3Y) 21.7%
EPS growth (1Y) -9.6%
EPS CAGR (3Y) 32.3%
Operating cash flow growth (1Y) -11.5%
Operating cash flow CAGR (3Y) 6.2%
Free cash flow growth (1Y) -10.2%
Free cash flow CAGR (3Y) 7.0%

Profitability

14 metrics
MetricNVS
Gross margin 77.4%
EBITDA margin –
Operating margin 31.2%
Pretax margin 28.3%
Net margin 28.8%
FCF margin 35.4%
Operating cash flow margin 33.6%
Return on equity 31.5%
Return on assets 10.6%
Return on invested capital 34.9%
Return on capital employed 19.3%
Asset turnover 0.5x
Cash conversion (OCF / net income) 1.4x
Stock comp / revenue –

Financial Health

11 metrics
MetricNVS
Debt / assets 7.9%
Debt / equity 0.2x
Net debt / EBITDA –
Debt / FCF 0.5x
Liabilities / assets 65.6%
Equity / assets 34.4%
Interest coverage 36.7x
Current ratio 0.9x
Quick ratio 0.5x
Cash ratio 0.2x
Altman Z-score –

Shareholder Returns

7 metrics
MetricNVS
Dividend yield 3.1%
Net buyback yield -1.5%
Shareholder yield 1.6%
Payout ratio (earnings) –
Payout ratio (FCF) –
Dividend growth (1Y) –
Dividend CAGR (3Y) –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNVS
Forward P/E 16.6xFY2026
EPS, next fiscal year $9.26FY2026
EPS growth, next FY +3.1%FY2026
EPS growth, the year after +1.2%
Revenue, next fiscal year $53.93BFY2026
Revenue growth, next FY -1.1%FY2026
Revenue growth, the year after +19.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNVS
Held by institutions 7.0%
Institutions holding 1,607
Change in shares held, QoQ -5.9%
Institutions buying 662
Institutions selling 560
Buyers to sellers 1.18

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which pays a higher dividend?

Only one of these companies pays a dividend: Novartis Ag (NVS) 3.08%.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.